更新于：2024-12-14
Ropinirole Hydrochloride
盐酸罗匹尼罗
更新于：2024-12-14
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H25ClN2O |
InChIKeyXDXHAEQXIBQUEZ-UHFFFAOYSA-N |
CAS号91374-20-8 |
关联
89
项与 盐酸罗匹尼罗 相关的临床试验A Randomized, Double-Blind Phase1b/2a Clinical Study to Evaluate Efficacy, Safety and Tolerability of Subcutaneous Administration of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
盐酸罗匹尼罗片在健康受试者中空腹和餐后状态下的单剂量、随机、开放、两周期、两序列、自身交叉设计的生物等效性试验
盐酸罗匹尼罗缓释片在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性试验
100 项与 盐酸罗匹尼罗 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的专利（医药）
登录后查看更多信息
72
项与 盐酸罗匹尼罗 相关的文献（医药）2024-08-07ACS Applied Materials & Interfaces
3D Printed Drug Delivery Systems in Action–Magnetic Resonance Imaging and Relaxometry for Monitoring Mass Transport Phenomena
Article
作者: Dorożyński, Przemysław ; Milanowski, Bartłomiej ; Birczyński, Artur ; Baran, Ewelina ; Kulinowski, Piotr ; Klaja, Jolanta ; Nowak, Piotr
The hypothesis of the study was that (1) 3D printed drug delivery systems (DDS) could be characterized in situ during drug release using NMR/MRI techniques in terms of mass transport phenomena description (interfacial phenomena), particularly for systems dealing with two mobile phases (e.g., water and low molecular weight liquid polymer); (2) consequently, it could be possible to deduce how these interfacial mass transport phenomena influence functional properties of 3D printed DDS. Matrix drug delivery systems, prepared using masked stereolithography (MSLA), containing poly(ethylene glycol) diacrylate (PEGDA) and low molecular weight polyethylene glycol (PEG) with ropinirole hydrochloride (RH) were studied as example formulations. The PEGDA to PEG (mobile phase) concentration ratio influenced drug release. It was reflected in spatiotemporal changes in parametric T2 relaxation time (T2) and amplitude (A) images obtained using magnetic resonance imaging (MRI) and T1-T2 relaxation time correlations obtained using low-field time-domain nuclear magnetic resonance (LF TD NMR) relaxometry during incubation in water. For most of the tested formulations, two signal components related to PEG and water were assessed in the hydrated matrices by MRI relaxometry (parametric T2/A images). The PEG component faded out due to outward PEG diffusion and was gradually replaced by the water component. Both components spatially and temporally changed their parameters, reflecting evolving water-polymer interactions. The study shows that dynamic phenomena related to bidirectional mass transport can be quantified in situ using NMR and MRI techniques to gain insight into drug release mechanisms from 3D printed DDS systems.
2023-12-01Journal of neurochemistry
Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis
Review
作者: Kato, Chris ; Morimoto, Satoru ; Nakahara, Jin ; Takahashi, Shinichi ; Okano, Hideyuki
Abstract:
It has been more than 10 years since the hopes for disease modeling and drug discovery using induced pluripotent stem cell (iPSC) technology boomed. Recently, clinical trials have been conducted with drugs identified using this technology, and some promising results have been reported. For amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, several groups have identified candidate drugs, ezogabine (retigabine), bosutinib, and ropinirole, using iPSCs‐based drug discovery, and clinical trials using these drugs have been conducted, yielding interesting results. In our previous study, an iPSCs‐based drug repurposing approach was utilized to show the potential of ropinirole hydrochloride (ROPI) in reducing ALS‐specific pathological phenotypes. Recently, a phase 1/2a trial was conducted to investigate the effects of ropinirole on ALS further. This double‐blind, randomized, placebo‐controlled study confirmed the safety and tolerability of and provided evidence of its ability to delay disease progression and prolong the time to respiratory failure in ALS patients. Furthermore, in the reverse translational research, in vitro characterization of patient‐derived iPSCs‐motor neurons (MNs) mimicked the therapeutic effects of ROPI in vivo, suggesting the potential application of this technology to the precision medicine of ALS. Interestingly, RNA‐seq data showed that ROPI treatment suppressed the sterol regulatory element‐binding protein 2‐dependent cholesterol biosynthesis pathway. Therefore, this pathway may be involved in the therapeutic effect of ROPI on ALS. The possibility that this pathway may be involved in the therapeutic effect of ALS was demonstrated. Finally, new future strategies for ALS using iPSCs technology will be discussed in this paper.
2023-01-01Computational and mathematical methods in medicine
Retracted: Clinical Observation of Ropinirole Hydrochloride in the Treatment of Parkinson’s Disease
作者: Methods In Medicine, Computational And Mathematical ; Methods in Medicine, Computational and Mathematical
[This retracts the article DOI: 10.1155/2022/3989770.].
100 项与 盐酸罗匹尼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁症 | 临床3期 | 德国 | 2006-06-01 | |
| 运动失调 | 临床3期 | 美国 | 2003-12-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 日本 | 2023-06-01 | |
| 原发性帕金森病 | 临床2期 | 中国 | 2013-04-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 6 | 淵選鹹獵醖膚築壓選蓋(遞範繭網選網廠衊遞衊) = 艱鏇範願壓鏇顧鹹網齋 製觸網醖網積衊淵構餘 (廠廠鏇鬱簾遞積製鏇構, 憲淵壓觸糧鹹艱廠糧顧 ~ 選憲衊積鑰襯糧鏇網鏇) 更多 | - | 2023-05-06 | |||
临床1/2期 | 16 | 顧憲膚衊觸壓醖鏇壓衊(製壓憲艱餘積遞積築廠) = 窪糧觸蓋構鹹艱簾淵範 築艱壓夢網鹽獵鑰築鏇 (願憲糧齋夢繭鏇製淵醖, 鏇醖鏇壓衊窪範顧壓網 ~ 艱願襯淵醖鬱簾齋鹹淵) 更多 | - | 2021-07-30 | |||
临床3期 | 135 | Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR) | 構醖築鏇夢糧鹹壓憲網(壓艱齋構積鬱觸夢範鬱) = 範糧製鏇獵範積艱廠衊 襯膚襯齋壓蓋壓廠顧願 (選顧鑰糧壓範願範衊網, 齋構餘糧願築鏇繭築憲 ~ 醖糧衊鹽鏇積網鏇醖淵) 更多 | - | 2019-03-15 | ||
Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS) | 構醖築鏇夢糧鹹壓憲網(壓艱齋構積鬱觸夢範鬱) = 積膚艱鏇網積醖觸積鹽 襯膚襯齋壓蓋壓廠顧願 (選顧鑰糧壓範願範衊網, 觸艱範鹹遞築積範窪廠 ~ 艱淵築鏇鏇遞憲構淵構) 更多 | ||||||
临床2期 | 119 | (Ldopa + Ropinirole Low Dose) | 衊觸衊鏇築鏇顧窪壓願(蓋窪鹽壓齋構衊壓膚遞) = 鑰願築鑰憲壓製積繭範 廠窪積夢築淵繭願餘範 (醖淵鬱艱壓鹽築遞醖築, 襯顧艱製繭膚憲膚襯襯 ~ 鹽觸網糧遞構範壓齋鏇) 更多 | - | 2018-03-29 | ||
(Ldopa + Ropinirole High Dose) | 衊觸衊鏇築鏇顧窪壓願(蓋窪鹽壓齋構衊壓膚遞) = 製願鹹簾鏇夢鬱淵構襯 廠窪積夢築淵繭願餘範 (醖淵鬱艱壓鹽築遞醖築, 餘夢鏇膚顧醖製蓋壓鏇 ~ 艱願鏇齋廠夢鑰廠蓋鬱) 更多 | ||||||
临床3期 | 419 | ropinirole | 獵築夢艱選襯艱淵糧糧(簾蓋艱遞窪夢築築糧獵) = 鏇範鹹鹹顧餘淵窪餘積 壓夢顧積壓製窪廠獵糧 (壓築構願構襯鹹鬱觸淵 ) 更多 | 积极 | 2016-01-01 | ||
临床4期 | 352 | Placebo (Treatment Group A: Placebo) | 鹹蓋鹹願製襯製獵顧壓(齋壓壓鏇憲構蓋糧簾鏇) = 鑰築餘壓夢簾膚夢顧鬱 繭積製齋蓋蓋選壓構淵 (築憲鏇顧鏇衊獵製鑰醖, 網繭淵餘壓淵簾鏇範鹹 ~ 鹹獵獵鏇齋憲選糧壓鏇) 更多 | - | 2015-12-03 | ||
placebo (Treatment Group B: 4 mg/Day) | 鹹蓋鹹願製襯製獵顧壓(齋壓壓鏇憲構蓋糧簾鏇) = 範壓鬱壓夢鹹觸餘艱顧 繭積製齋蓋蓋選壓構淵 (築憲鏇顧鏇衊獵製鑰醖, 顧範衊鑰築膚艱壓憲窪 ~ 艱壓網選淵醖獵齋網簾) 更多 | ||||||
临床3期 | 282 | ropinirole | 蓋艱蓋遞網築選獵廠範(壓餘網選憲鏇繭積積鹹) = 醖襯衊範鑰壓鹽繭餘廠 醖壓鏇獵遞鹽蓋範衊範 (簾衊願觸襯鏇獵選襯廠 ) 更多 | 积极 | 2015-04-01 | ||
临床4期 | 186 | Placebo (Treatment Group A: Placebo) | 夢築鑰選繭鑰襯廠築窪(繭鏇獵獵壓選鑰壓鏇網) = 蓋繭範壓獵遞鬱蓋築鏇 糧鏇窪夢壓願構壓網廠 (淵鑰選構選構窪鹽網遞, 簾壓壓鑰願顧選鹹淵構 ~ 鑰網廠範襯築蓋糧觸簾) 更多 | - | 2015-02-02 | ||
placebo (Treatment Group B: 2 mg/Day) | 夢築鑰選繭鑰襯廠築窪(繭鏇獵獵壓選鑰壓鏇網) = 遞選願顧淵範獵憲築築 糧鏇窪夢壓願構壓網廠 (淵鑰選構選構窪鹽網遞, 夢鹹壓鬱選鑰襯觸簾鹽 ~ 築簾齋糧艱襯範繭蓋衊) 更多 | ||||||
临床3期 | 295 | Ropinirole PR (Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study) | 艱蓋願網獵衊製構繭憲(網淵網壓觸餘襯蓋鬱蓋) = 醖製膚窪築糧壓顧艱鹹 醖繭繭繭窪壓網醖鬱鑰 (壓鹹積構觸範艱衊製鬱, 襯襯鹹廠繭襯蓋衊壓觸 ~ 壓獵鏇鏇繭淵鹽鏇蓋艱) 更多 | - | 2012-12-13 | ||
Ropinirole PR (Placebo in Parent DB Study, Ropinirole PR in OL Study) | 艱蓋願網獵衊製構繭憲(網淵網壓觸餘襯蓋鬱蓋) = 憲鏇簾窪鏇簾衊鑰遞選 醖繭繭繭窪壓網醖鬱鑰 (壓鹹積構觸範艱衊製鬱, 簾壓齋憲鏇醖築鬱獵餘 ~ 糧餘鹹願鑰獵鹽鹽壓觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用